[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhang et al., 2020 - Google Patents

Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy

Zhang et al., 2020

View HTML
Document ID
14810055863680655774
Author
Zhang C
Liu Y
Publication year
Publication venue
Frontiers in immunology

External Links

Snippet

Checkpoint blockade therapy, for example using antibodies against CTLA-4 and PD-1/PD- L1, relieves T cells from the suppression by inhibitory checkpoints in the tumor microenvironment; thereby achieving good outcomes in the treatment of different cancer …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Zhang et al. Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy
Cao et al. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Khan et al. NK cell-based immune checkpoint inhibition
Melaiu et al. Influence of the tumor microenvironment on NK cell function in solid tumors
Minetto et al. Harnessing NK cells for cancer treatment
Vago et al. Immune escape and immunotherapy of acute myeloid leukemia
Khair et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
Lv et al. Immunotherapy: reshape the tumor immune microenvironment
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Muenst et al. The immune system and cancer evasion strategies: therapeutic concepts
Hou et al. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors
Fuertes et al. Leveraging NKG2D ligands in immuno-oncology
Kabacaoglu et al. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options
Lin et al. Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy
Leone et al. Actors on the scene: immune cells in the myeloma niche
Catakovic et al. T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Rothlin et al. Lifting the innate immune barriers to antitumor immunity
Jacobs et al. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect
Beyar-Katz et al. Novel approaches to acute myeloid leukemia immunotherapy
Beavis et al. Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses
Calì et al. Tuning cancer fate: the unremitting role of host immunity
Atanackovic et al. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Lindau et al. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
Alfarra et al. Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy
Spel et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma